Lineage Cell Therapeutics, Inc. Earnings Per Share (Basic)
Lineage Cell Therapeutics, Inc. (LCTX) reported Earnings Per Share (Basic) of $0.01 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was $0.01.
- Lineage Cell Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.02.
- Lineage Cell Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.13.
- Lineage Cell Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-06-30 was -$0.13.
- Lineage Cell Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$0.28.
- Lineage Cell Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$0.09.
- Lineage Cell Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$0.12.
- Lineage Cell Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$0.15.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.01 10-Q · filed 2026-08-06 | -$0.01 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | -$0.02 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | -$0.28 10-K · filed 2026-03-05 | |||
| 2025-09-30 | -$0.13 10-Q · filed 2025-11-06 | -$0.28 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | -$0.13 10-Q · filed 2026-08-06 | -$0.15 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | -$0.02 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | -$0.09 10-K · filed 2026-03-05 | |||
| 2024-09-30 | -$0.02 10-Q · filed 2025-11-06 | -$0.08 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | -$0.03 10-Q · filed 2025-08-12 | -$0.07 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | -$0.04 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$0.03 10-K · filed 2024-03-07 | -$0.12 10-K · filed 2025-03-10 | ||
| 2023-09-30 | -$0.04 10-Q · filed 2024-11-14 | -$0.10 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | -$0.03 10-Q · filed 2024-08-08 | -$0.06 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$0.03 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$0.03 10-K · filed 2024-03-07 | -$0.15 10-K · filed 2024-03-07 | ||
| 2022-09-30 | -$0.04 10-K · filed 2024-03-07 | -$0.12 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | -$0.04 10-K · filed 2024-03-07 | -$0.08 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$0.04 10-K · filed 2024-03-07 | |||
| 2021-12-31 | -$0.17 10-K · filed 2023-03-09 | -$0.26 10-K · filed 2023-03-09 | ||
| 2021-09-30 | -$0.05 10-K · filed 2023-03-09 | -$0.09 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | -$0.03 10-K · filed 2023-03-09 | -$0.04 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$0.01 10-K · filed 2023-03-09 | |||
| 2020-12-31 | $0.01 10-K · filed 2022-03-10 | |||
| 2020-09-30 | -$0.05 10-K · filed 2022-03-10 | -$0.15 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | -$0.04 10-K · filed 2022-03-10 | -$0.10 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$0.06 10-K · filed 2022-03-10 | |||
| 2019-12-31 | -$0.03 10-K · filed 2021-03-11 | |||
| 2019-09-30 | -$0.11 10-K · filed 2021-03-11 | -$0.05 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | -$0.20 10-K · filed 2021-03-11 | $0.07 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $0.30 10-K · filed 2021-03-11 | |||
| 2018-12-31 | -$0.36 10-K · filed 2020-03-12 | |||
| 2018-09-30 | $0.53 10-K · filed 2020-03-12 | -$0.01 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | -$0.03 10-K · filed 2020-03-12 | -$0.53 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | -$0.50 10-K · filed 2020-03-12 | |||
| 2017-12-31 | -$0.58 10-K · filed 2019-03-14 | -$0.17 10-K · filed 2018-03-15 | ||
| 2017-09-30 | $0.12 10-K · filed 2019-03-14 | $0.47 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | -$0.11 10-K · filed 2019-03-14 | $0.35 10-Q · filed 2018-08-02 | ||
| 2017-03-31 | $0.46 10-K · filed 2019-03-14 | |||
| 2016-12-31 | -$0.05 10-K · filed 2018-03-15 | $0.13 derived: net income ÷ weighted average shares · filed 2018-03-15 | $0.39 derived: net income ÷ weighted average shares · filed 2018-03-15 | $0.35 10-K · filed 2018-03-15 |
| 2016-09-30 | $0.30 10-K · filed 2018-03-15 | $569.00 derived: net income ÷ weighted average shares · filed 2017-11-09 | $0.40 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $0.26 10-K · filed 2018-03-15 | $0.08 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | -$0.19 10-K · filed 2018-03-15 | |||
| 2015-12-31 | -$0.04 derived: net income ÷ weighted average shares · filed 2018-03-15 | -$0.17 derived: net income ÷ weighted average shares · filed 2018-03-15 | -$0.35 derived: net income ÷ weighted average shares · filed 2018-03-15 | -$0.59 10-K · filed 2018-03-15 |
| 2015-09-30 | -$0.18 10-Q · filed 2016-11-04 | -$301.19 derived: net income ÷ weighted average shares · filed 2016-11-04 | -$0.43 10-Q · filed 2016-11-04 | |
| 2015-06-30 | -$0.12 10-Q · filed 2016-08-09 | -$0.25 10-Q · filed 2016-08-09 | ||
| 2014-12-31 | -$0.55 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |